Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:biosimilar |
| gptkbp:activeIngredient |
gptkb:ranibizumab
|
| gptkbp:approvalYear |
2022
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Cimerli
|
| gptkbp:form |
solution for injection
|
| gptkbp:indication |
gptkb:diabetic_macular_edema
gptkb:neovascular_(wet)_age-related_macular_degeneration diabetic retinopathy macular edema following retinal vein occlusion |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Coherus_BioSciences
|
| gptkbp:mechanismOfAction |
VEGF-A inhibitor
|
| gptkbp:routeOfAdministration |
intravitreal injection
|
| gptkbp:bfsParent |
gptkb:CIMERLI
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
ranibizumab-eqrn
|